Lisinopril vs Losartan: What to Do When One Fails

How Lisinopril and Losartan Block the Same Pathway Differently

Both drugs suppress the renin-angiotensin-aldosterone system (RAAS), but they do it at different points. Lisinopril inhibits ACE, the enzyme that converts angiotensin I to angiotensin II. Losartan blocks the AT1 receptor that angiotensin II binds to. That single mechanistic difference explains almost every clinically meaningful distinction between them.

The Bradykinin Problem with ACE Inhibitors

ACE does not only convert angiotensin I. It also degrades bradykinin. When lisinopril blocks ACE, bradykinin accumulates. Excess bradykinin causes the dry, persistent cough that affects roughly 10-15% of patients taking any ACE inhibitor, and it drives the rare but life-threatening angioedema seen in approximately 0.1-0.3% of users. [1] Losartan does not touch ACE, so bradykinin accumulation is not a mechanism-driven side effect.

What Losartan Does That Lisinopril Cannot

Because losartan blocks the AT1 receptor directly, angiotensin II still forms but cannot exert its vasoconstrictive and aldosterone-releasing effects. This also means angiotensin II is free to act on AT2 receptors, which some researchers believe may add vasodilatory and antiproliferative benefit. Whether that distinction matters clinically remains debated, but the absence of bradykinin accumulation is the practical reason millions of patients who cannot tolerate an ACE inhibitor are maintained on ARBs.

Head-to-Head Trial Evidence: What the Data Actually Show

No single trial has directly compared lisinopril to losartan as primary agents in a large randomized design. The evidence base draws from two landmark trials that each tested one drug against a different comparator, plus mechanistic crossover studies.

ALLHAT: Lisinopril Against the Gold Standard

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT, N=33,357) compared chlorthalidone, amlodipine, and lisinopril in high-risk hypertensive patients over a mean follow-up of 4.9 years. The primary outcome (combined fatal coronary heart disease or nonfatal MI) was similar across arms. [2] However, lisinopril showed higher rates of stroke (relative risk 1.15, 95% CI 1.02-1.30) and combined cardiovascular disease compared to chlorthalidone, driven largely by smaller blood pressure reductions in Black participants. The trial did not include losartan.

LIFE: Losartan's Stroke Reduction Signal

The Losartan Intervention For Endpoint Reduction in Hypertension trial (LIFE, N=9,193) randomized patients with hypertension and electrocardiographic left ventricular hypertrophy (LVH) to losartan 50-100 mg or atenolol 50-100 mg. At a mean follow-up of 4.8 years, losartan reduced the primary composite of cardiovascular death, stroke, and MI by 13% (relative risk 0.87, P<0.001), with a 25% reduction in stroke driving most of that benefit. [3] Losartan also produced significantly greater LVH regression than atenolol despite similar blood pressure reductions, suggesting a blood-pressure-independent benefit in cardiac remodeling.

Indirect Comparisons and Meta-Analyses

A 2018 Cochrane meta-analysis of first-line antihypertensives found ACE inhibitors and ARBs produce nearly identical reductions in all-cause mortality and major cardiovascular events when blood pressure control is equivalent. [4] The practical takeaway: the choice between lisinopril and losartan for uncomplicated hypertension often comes down to tolerability and cost, not differential efficacy.

The Five Situations That Force a Switch

1. ACE Inhibitor-Induced Cough

This is the most common reason clinicians move a patient from lisinopril to losartan. The cough is dry, non-productive, and often described as a tickle or scratch at the back of the throat. It does not resolve with dose reduction. The only fix is stopping the ACE inhibitor. Switching to losartan 50 mg once daily is the standard next step and typically resolves the cough within 1-4 weeks of stopping lisinopril.

2. Angioedema on Lisinopril

ACE inhibitor-induced angioedema is a medical emergency. It typically involves the lips, tongue, oropharynx, or larynx and can be fatal. After an episode of angioedema on lisinopril or any ACE inhibitor, the entire ACE inhibitor class is contraindicated permanently. ARBs carry a small risk of cross-reactive angioedema (estimated at 0.3-0.7% in patients with prior ACE inhibitor angioedema) [5], so the switch to losartan is reasonable but requires counseling and close early monitoring. Do not rechallenge with another ACE inhibitor.

3. Inadequate Blood Pressure Control on Losartan

Losartan at 50 mg once daily is a starting dose, not a ceiling. If blood pressure remains above target (typically <130/80 mmHg per the 2017 ACC/AHA guideline), the first move is to uptitrate losartan to 100 mg once daily before abandoning the drug or adding an agent. If 100 mg does not achieve target, adding a thiazide-type diuretic (hydrochlorothiazide 12.5-25 mg, or the fixed-dose losartan/HCTZ combination) is well-supported before considering a class switch.

4. Hyperkalemia or Acute Kidney Injury

Both drugs raise serum potassium and can precipitate acute kidney injury in specific settings: volume depletion, bilateral renal artery stenosis, concurrent NSAID use, or a GFR below 30 mL/min/1.73 m2. Neither agent is clearly safer in these settings. If either drug causes a potassium rise above 5.5 mEq/L or a creatinine increase greater than 30% from baseline, the drug should be held, the precipitating cause corrected, and the dose reduced or the agent switched to a calcium channel blocker or thiazide.

5. Pregnancy

Both lisinopril and losartan are FDA Pregnancy Category D (now described under the PLLR framework as contraindicated in the second and third trimesters due to fetal renal toxicity, oligohydramnios, and neonatal death). [6] Neither drug is an acceptable alternative to the other during pregnancy. Methyldopa, labetalol, and nifedipine are the preferred agents.

Dosing Reference Table

| Situation | Lisinopril Dose | Losartan Dose | Notes | |---|---|---|---| | Hypertension (start) | 10 mg once daily | 50 mg once daily | Uptitrate at 2-4 weeks | | Hypertension (max) | 40 mg once daily | 100 mg once daily | Check renal function/K+ | | Heart failure (start) | 2.5-5 mg once daily | 25 mg once daily | Lower start in hypotension | | Heart failure (target) | 20-40 mg once daily | 50-150 mg once daily | Titrate over weeks | | Post-MI (start) | 2.5-5 mg once daily | Not first-line post-MI | ACE inhibitor preferred post-MI | | CKD with proteinuria | 10-40 mg once daily | 50-100 mg once daily | ARB preferred in type 2 DM nephropathy | | Switching: ACE cough | Stop lisinopril | Start losartan 50 mg | Wait 48 h after stopping |

Specific Populations: Who Gets Which Drug First

Heart Failure with Reduced Ejection Fraction

Lisinopril carries a Class I indication for HFrEF based on the ATLAS trial and decades of ACE inhibitor outcome data. Losartan is a Class I alternative when ACE inhibitor intolerance is present. The HEAAL trial (N=3,846) showed losartan 150 mg reduced all-cause death or hospitalization for heart failure by 10% compared to losartan 50 mg (HR 0.90, P<0.025), confirming that dose matters. [7] Do not combine an ACE inhibitor with an ARB in HFrEF; the combination increases adverse events without additional mortality benefit per ONTARGET. [8]

Diabetic Nephropathy

For type 2 diabetic nephropathy, ARBs (specifically losartan and irbesartan) have the stronger evidence base. The RENAAL trial (N=1,513) showed losartan 50-100 mg reduced the risk of the composite renal endpoint (doubling of serum creatinine, ESRD, or death) by 16% versus placebo in patients with type 2 diabetes and nephropathy. [9] ACE inhibitors are also effective in this population, but guideline preference has shifted toward ARBs for type 2 DM nephropathy specifically.

Hypertension with Left Ventricular Hypertrophy

The LIFE data above (25% stroke reduction, significant LVH regression) make losartan the preferred first-line RAAS agent in patients with documented LVH on ECG or echocardiography.

Black Patients with Hypertension

ALLHAT data and subsequent analyses show ACE inhibitors produce smaller blood pressure reductions in Black patients compared to white patients, likely related to lower average renin activity. This translates to less cardiovascular event reduction. The 2017 ACC/AHA and 2022 AHA scientific statement recommend thiazide-type diuretics or calcium channel blockers as preferred first-line agents in Black patients. [10] If a RAAS agent is added, losartan and lisinopril perform more similarly when combined with a diuretic.

The Switch Protocol: Step-by-Step

When a patient needs to move from lisinopril to losartan (or vice versa), a structured approach reduces the risk of rebound hypertension and monitoring gaps.

Step 1. Confirm the failure mode. Is this a tolerability failure (cough, angioedema, hyperkalemia) or an efficacy failure (blood pressure not at goal despite maximum dose)? The answer changes the next step.

Step 2. Check baseline labs before switching. Serum creatinine, eGFR, and potassium within the past 3 months. If creatinine has risen more than 30% from pre-treatment baseline, investigate for bilateral renal artery stenosis before starting any RAAS agent.

Step 3. Time the switch. For cough or tolerability: stop lisinopril, wait 48 hours, then start losartan 50 mg once daily. For an angioedema history: wait a minimum of 6 weeks after the angioedema episode before starting an ARB, and counsel the patient on the residual cross-reactivity risk.

Step 4. Set an equivalent dose target. Lisinopril 10 mg daily and losartan 50 mg daily produce broadly comparable RAAS blockade and blood pressure reduction. Lisinopril 20-40 mg roughly corresponds to losartan 100 mg. These are approximations, not fixed equivalencies.

Step 5. Recheck labs at 1-2 weeks. Serum creatinine and potassium. A creatinine rise of up to 30% from new baseline is acceptable and expected with RAAS initiation; above that threshold, reduce the dose or hold the drug.

Step 6. Recheck blood pressure at 4 weeks. If still above target, uptitrate before adding a new agent.

Combination Therapy: When Neither Drug Alone Is Enough

Most hypertensive patients need more than one agent to reach <130/80 mmHg. When lisinopril or losartan at maximum dose does not achieve target, the standard add-on sequence per ACC/AHA 2017 is:

1. Add a thiazide-type diuretic (chlorthalidone 12.5-25 mg preferred over HCTZ based on ALLHAT data).
2. Add a long-acting dihydropyridine calcium channel blocker (amlodipine 5-10 mg).
3. Consider adding spironolactone 25-50 mg for resistant hypertension (3+ agents at maximum doses).

The fixed-dose combination of losartan 50 mg plus hydrochlorothiazide 12.5 mg (available as Hyzaar and generics) is a practical option that improves adherence while adding meaningful additional blood pressure reduction.

Do not combine lisinopril with losartan. ONTARGET (N=25,620) showed that dual RAAS blockade with ramipril plus telmisartan produced more hypotension, syncope, and renal failure than either agent alone, with no reduction in the primary cardiovascular endpoint. [8]

Monitoring Parameters After Any RAAS Change

Regardless of direction (ACE to ARB or ARB to ACE), every RAAS switch or dose change requires:

• Potassium: Check at 1-2 weeks. Hold if K+ exceeds 5.5 mEq/L. Target K+ 4.0-5.0 mEq/L.
• Serum creatinine / eGFR: Check at 1-2 weeks. A rise of up to 30% is physiologically expected and not a reason to stop the drug. Above 30%, investigate and reduce dose.
• Blood pressure: Recheck at 2-4 weeks after any dose change.
• Symptoms of hypotension: Dizziness, lightheadedness, especially in older adults or those on diuretics.

The 2022 AHA/ACC guideline on hypertension specifies that eGFR monitoring is "particularly important" in patients with baseline CKD stage 3b or higher (eGFR <45 mL/min/1.73 m2). [10]

Cost and Availability

Both drugs are available as inexpensive generics. As of 2025, lisinopril 10 mg and losartan 50 mg each cost under $10/month at major pharmacy chains using discount programs such as GoodRx. Cost is rarely the deciding factor when switching between them, but the fixed-dose losartan/HCTZ combination adds modest cost over individual generics.